Literature DB >> 8403737

The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.

K Groen1, M A Horan, N A Roberts, R S Gulati, B Miljkovic, E J Jansen, V Paramsothy, D D Breimer, C F van Bezooijen.   

Abstract

The influence of aging on the metabolism of phenazone (antipyrine), and the relationship between the formation of 3 phenazone metabolites and the metabolic clearance of theophylline in healthy and frail elderly women, were examined. Whereas the elimination half-life did not change, clearance of phenazone decreased by about 50% with age in healthy women receiving phenazone without theophylline. However, the summation of the urinary recovery of phenazone and the measured metabolites, expressed as percentage of the phenazone dose, was lower in the healthy elderly (37 +/- 9% vs 74 +/- 15%). In both healthy and frail females the clearance of formation of 4-hydroxy-phenazone and the metabolic clearance of theophylline correlated strongly (r = 0.93 and 0.90, respectively). In non-healthy elderly females, strong correlations were also observed between the other metabolic pathways of phenazone and the metabolic clearance of theophylline. Coadministration of theophylline in the elderly increased the percentage of the phenazone dose excreted as the measured metabolites. A considerably higher interindividual variability in the disposition of phenazone and theophylline was observed in the frail elderly women. This high degree of variability in drug metabolism may be one of the explanations for the problems often occurring after drug prescription in the elderly.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403737     DOI: 10.2165/00003088-199325020-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  26 in total

1.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

2.  Admission criteria for immunogerontological studies in man: the SENIEUR protocol.

Authors:  G J Ligthart; J X Corberand; C Fournier; P Galanaud; W Hijmans; B Kennes; H K Müller-Hermelink; G G Steinmann
Journal:  Mech Ageing Dev       Date:  1984-11       Impact factor: 5.432

Review 3.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

4.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

5.  Theophylline: a remarkable window to the hepatic microsomal oxidases.

Authors:  J W Jenne
Journal:  Chest       Date:  1982-05       Impact factor: 9.410

6.  Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach.

Authors:  J H Schellens; A R Janssens; J H van der Wart; E A van der Velde; D D Breimer
Journal:  Eur J Clin Invest       Date:  1989-10       Impact factor: 4.686

7.  Cimetidine-theophylline interaction: effects of age and cimetidine dose.

Authors:  I A Cohen; C E Johnson; R R Berardi; M L Hyneck; S R Achem
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

8.  Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.

Authors:  R Dahlqvist; L Bertilsson; D J Birkett; M Eichelbaum; J Säwe; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

9.  Cigarette smoking and theophylline clearance and metabolism.

Authors:  J J Grygiel; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

10.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

View more
  7 in total

Review 1.  Drug metabolism and ageing.

Authors:  M T Kinirons; M S O'Mahony
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 2.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

Review 3.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

4.  Do geriatric conditions increase risk of adverse drug reactions in ambulatory elders? Results from the VA GEM Drug Study.

Authors:  Michael A Steinman; Joseph T Hanlon; Richard J Sloane; W John Boscardin; Kenneth E Schmader
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-02-14       Impact factor: 6.053

5.  Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

Authors:  J B Dumond; J L Adams; H M A Prince; R L Kendrick; R Wang; S H Jennings; S Malone; N White; C Sykes; A H Corbett; K B Patterson; A Forrest; A D M Kashuba
Journal:  HIV Med       Date:  2013-02-24       Impact factor: 3.180

6.  p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.

Authors:  J B Dumond; J W Collins; M L Cottrell; C R Trezza; Hma Prince; C Sykes; C Torrice; N White; S Malone; R Wang; K B Patterson; N E Sharpless; A Forrest
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-12-26

7.  Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.

Authors:  J B Dumond; J Chen; M Cottrell; C R Trezza; Hma Prince; C Sykes; C Torrice; N White; S Malone; R Wang; K B Patterson; N E Sharpless; A Forrest
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.